Strategi mix-and-match vaksin COVID-19, seberapa efektifkah?

Rita Khairani

doi:10.18051/jbiomedkes.2021.v4.87-89

Strategi mix-and-match vaksin COVID-19, seberapa efektifkah?

Jurnal Biomedika dan Kesehatan ◽

10.18051/jbiomedkes.2021.v4.87-89 ◽

2021 ◽

Vol 4 (3) ◽

pp. 87-89

Author(s):

Rita Khairani

Keyword(s):

Vectored Vaccine ◽

Mix And Match

Dibandingkan dengan perkembangan vaksin COVID-19, kemunculan banyak varian baru menyebabkan peningkatan mortalitas dan morbiditas, distribusi vaksin secara global, ketersediaan suplai vaksin yang terbatas dan kejadian ikutan pasca imunisasi. Hal ini memunculkan kekhawatiran penurunan efektivitas vaksin yang telah ada. Setelah laporan kejadian tromboemboli akibat penggunaan ChAdOx1-nCoV-19 dari AstraZeneca, beberapa negara Eropa mulai meneliti tentang penggunaan vaksin yang berbeda dengan dosis pertama atau yang disebut strategi mix-and-match atau vaksin heterolog.(1) Vaksin heterolog melibatkan pemberian antigen penyakit yang sama atau serupa melalui dua tipe vaksin berbeda, dosis pertama untuk membentuk sistem imun dan dosis berikutnya dengan tipe berbeda untuk meningkatkan respon imun.(2) Beberapa jenis vaksin yang banyak diteliti dalam konsep vaksin heterolog ini diantaranya kombinasi vaksin chimpanzee adenovirus-vectored vaccine (ChAdOx 1 nCoV-19) atau AstraZeneca dengan vaksin mRNA-1273 atau vaksin Moderna, dan vaksin BNT162b2 atau vaksin Pfizer.(3,4)

Download Full-text

Faculty Opinions recommendation of Mix and match: investigating heteromeric and heterotypic gap junction channels in model systems and native tissues.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718285864.793491698 ◽

2014 ◽

Cited By ~ 1

Author(s):

Eric Beyer

Keyword(s):

Gap Junction ◽

Model Systems ◽

Gap Junction Channels ◽

Mix And Match

Download Full-text

Faculty Opinions recommendation of Virally-vectored vaccine candidates against white-nose syndrome induce anti-fungal immune response in little brown bats (Myotis lucifugus).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735680577.793560038 ◽

2019 ◽

Author(s):

Joseph Heitman

Keyword(s):

Immune Response ◽

Myotis Lucifugus ◽

Vaccine Candidates ◽

White Nose Syndrome ◽

Vectored Vaccine ◽

Anti Fungal ◽

Little Brown Bats

Download Full-text

Plug-and-Play, Mix-and-Match: A Capital Systems Theory of Digital Technology Platforms

SSRN Electronic Journal ◽

10.2139/ssrn.3537197 ◽

2020 ◽

Author(s):

L. Lynne Kiesling

Keyword(s):

Systems Theory ◽

Digital Technology ◽

Plug And Play ◽

Technology Platforms ◽

Mix And Match

Download Full-text

A ‘mix and match’ approach to SARS-CoV-2 vaccination

Nature Medicine ◽

10.1038/s41591-021-01463-x ◽

2021 ◽

Author(s):

Meagan E. Deming ◽

Kirsten E. Lyke

Keyword(s):

Mix And Match

Download Full-text

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

Nature Communications ◽

10.1038/s41467-021-23173-1 ◽

2021 ◽

Vol 12 (1) ◽

Author(s):

Alexandra J. Spencer ◽

Paul F. McKay ◽

Sandra Belij-Rammerstorfer ◽

Marta Ulaszewska ◽

Cameron D. Bissett ◽

...

Keyword(s):

Immune Response ◽

Clinical Trials ◽

T Cells ◽

Immune Responses ◽

Viral Vectors ◽

Cytotoxic T Cells ◽

Antibody Responses ◽

Limited Data ◽

Vectored Vaccine ◽

Cellular Immune

AbstractSeveral vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet there is limited data on the immune response induced by heterologous vaccination regimens using alternate vaccine modalities. Here, we present a detailed description of the immune response, in mice, following vaccination with a self-amplifying RNA (saRNA) vaccine and an adenoviral vectored vaccine (ChAdOx1 nCoV-19/AZD1222) against SARS-CoV-2. We demonstrate that antibody responses are higher in two-dose heterologous vaccination regimens than single-dose regimens. Neutralising titres after heterologous prime-boost were at least comparable or higher than the titres measured after homologous prime boost vaccination with viral vectors. Importantly, the cellular immune response after a heterologous regimen is dominated by cytotoxic T cells and Th1+ CD4 T cells, which is superior to the response induced in homologous vaccination regimens in mice. These results underpin the need for clinical trials to investigate the immunogenicity of heterologous regimens with alternate vaccine technologies.

Download Full-text

DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination

Viruses ◽

10.3390/v13061046 ◽

2021 ◽

Vol 13 (6) ◽

pp. 1046

Author(s):

Gerardo Casucci ◽

Domenico Acanfora

Keyword(s):

Side Effects ◽

Disseminated Intravascular Coagulation ◽

Adverse Reactions ◽

Thrombus Formation ◽

European Countries ◽

European Medicines Agency ◽

Safety Committee ◽

Vectored Vaccine ◽

Short Time ◽

Prompt Diagnosis

In recent weeks, adverse reactions have been reported after administration of Oxford–AstraZeneca chimpanzee adenovirus vectored vaccine ChAdOx1 nCoV-19 (AZD1222), in particular thrombus formation, which has led several European Countries to discontinue administration of this vaccine. On March 8, 2021, the European Medicines Agency Safety Committee did not confirm this probable association. We report the case of a patient who developed disseminated intravascular coagulation after the first dose of Oxford-Astra Zeneca vaccine, which resolved in a few days with the administration of dexamethasone and enoxaparin. This work demonstrates the safety of the Oxford-Astra Zeneca vaccine and that any development of side effects can be easily managed with a prompt diagnosis and in a short time with a few commonly used drugs.

Download Full-text